D. Ross Camidge, MD, PhD, and Eric K. Singhi, MD, preview the SCLC and NSCLC abstracts they are anticipating at the 2026 World Conference on Lung Cancer.
|Videos|May 6, 2011
Elizabeth Blasiak Discusses the ONS Congress
Author(s)Elizabeth Blasiak, RN, MSN
Elizabeth Blasiak on the Significance of the ONS Congress
Advertisement
Elizabeth Blasiak, RN, MSN, OCN®, Medical Oncology, Smilow Cancer Hospital at Yale New Haven Hospital, New Haven, CT on the significance of the ONS congress.
Advertisement
Related to this article
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Advertisement
Advertisement
Trending on OncLive
1
Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance
2
Arlo-Cel Meets ORR End Point in BCMA-Pretreated, Quadruple-Class Exposed R/R Myeloma
3
Camidge and Singhi Highlight the Lung Cancer Abstracts to Watch at WCLC 2026
4
Frontline Mipletamig Triplet Drives Clinical Benefit in TP53-Mutated AML
5